Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs reported Q4 FY26 revenue of Rs. 703 crore (up 16.6%) and full-year revenue of Rs. 2,763 crore (up 12.2%), driven by 12.9% sample volume growth in Q4. EBITDA margin for FY26 stood at 27.2% (excluding one-time labour code cost of Rs. 30 crore). The company added 14 new labs and over 1,100 collection centers during the year. Key initiatives include the launch of Sovaaka (AI-powered precision health screening), hosting of Medllumina 2026 international conference, and acquisition of Shahbazkers Diagnostic Centre in Mumbai for Rs. 20 crore. Swasthfit preventive healthcare brand contributed 27% to total revenue. Management guided for early to mid-teens (13-15%) revenue growth for FY27 with margins expected in the 27-28% range. Capex guidance for FY27 is Rs. 100-120 crore. The company also incorporated a subsidiary in Dubai for international expansion over the next 3-5 years.
Management signaled focus on reinvesting for growth rather than margin expansion, expecting similar 27-28% EBITDA margins in FY27 despite ongoing infrastructure investments. Strong cash position of Rs. 1,526 crore provides flexibility for acquisitions and organic expansion.